Steatosis-Associated Fibrosis Estimator Score in Asian Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.

ABSTRACT:

Purpose

Recently, the steatosis-associated fibrosis estimator (SAFE) score was developed to predict significant fibrosis in primary care. We externally validated the SAFE score in Asian patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Materials and methods

We validated the SAFE score in 6229 patients who underwent transient elastography (TE) from 2012 to 2022. The sensitivities, specificities, negative predictive values, and positive predictive values of SAFE scores (two cutoffs: <0 and ≥100) for predicting fibrosis stage ≥2 were calculated.

Results

Based on TE results, the SAFE score had an area under the receiver operating characteristic curve of 0.753 (95% confidence interval 0.737-0.769), outperforming the Fibrosis-4 index (0.672) an

SUBMITTER: Kim K 

PROVIDER: S-EPMC12834604 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature